Thanks to the Ozbiota blogger for the heads up on the Annual...

Thanks to the Ozbiota blogger for the heads up on the Annual Report released last Friday.

I note the blogger's concerns about Lani's IP protection.

I was a little shocked at how close some of the patent expiries (in the US) were to be honest (excluding any extensions):

1. The LANI chemical structure patent expires 2017.
2. The LANI chemical form used in our inhaler expires 2021.
3. The Inhaler patent expires 2029.

I got Joe Patti to confirm a couple of things. Firstly, he doesnt think there is too much of a competitive threat to our Lani product from patent expiry No.1. Secondly, in regards to patent expiry 2, its up to the FDA to decide but he reckons a competitor using a different inhaler would still need to do a number of trials. I think we've discussed this before but I needed this degree of comfort re-confirmed.

It makes my blood boil that the previous management sat on this for so long, diverting much needed money to programs of questionable value (Vapendavir).